Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

345 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development?
Pearson ADJ, de Rojas T, Karres D, Reaman G, Scobie N, Fox E, Lesa G, Ligas F, Norga K, Nysom K, Pappo A, Weigel B, Weiner S, Vassal G. Pearson ADJ, et al. Among authors: vassal g. Lancet Oncol. 2022 Nov;23(11):1354-1357. doi: 10.1016/S1470-2045(22)00619-2. Lancet Oncol. 2022. PMID: 36328007 No abstract available.
Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development.
Bax DA, Little SE, Gaspar N, Perryman L, Marshall L, Viana-Pereira M, Jones TA, Williams RD, Grigoriadis A, Vassal G, Workman P, Sheer D, Reis RM, Pearson AD, Hargrave D, Jones C. Bax DA, et al. Among authors: vassal g. PLoS One. 2009;4(4):e5209. doi: 10.1371/journal.pone.0005209. Epub 2009 Apr 14. PLoS One. 2009. PMID: 19365568 Free PMC article.
Will the revised class waiver list make it?
Vassal G, Blanc P, Copland C, Pearson A. Vassal G, et al. Lancet Oncol. 2015 Sep;16(9):e425-e426. doi: 10.1016/S1470-2045(15)00233-8. Lancet Oncol. 2015. PMID: 26370347 No abstract available.
Implementation of mechanism of action biology-driven early drug development for children with cancer.
Pearson AD, Herold R, Rousseau R, Copland C, Bradley-Garelik B, Binner D, Capdeville R, Caron H, Carleer J, Chesler L, Geoerger B, Kearns P, Marshall LV, Pfister SM, Schleiermacher G, Skolnik J, Spadoni C, Sterba J, van den Berg H, Uttenreuther-Fischer M, Witt O, Norga K, Vassal G; Members of Working Group 1 of the Paediatric Platform of ACCELERATE. Pearson AD, et al. Among authors: vassal g. Eur J Cancer. 2016 Jul;62:124-31. doi: 10.1016/j.ejca.2016.04.001. Epub 2016 May 31. Eur J Cancer. 2016. PMID: 27258969 Review.
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D; SIOP Europe Neuroblastoma Group (SIOPEN). Ladenstein R, et al. Among authors: vassal g. Lancet Oncol. 2017 Apr;18(4):500-514. doi: 10.1016/S1470-2045(17)30070-0. Epub 2017 Mar 2. Lancet Oncol. 2017. PMID: 28259608 Clinical Trial.
Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.
Moreno L, Pearson ADJ, Paoletti X, Jimenez I, Geoerger B, Kearns PR, Zwaan CM, Doz F, Baruchel A, Vormoor J, Casanova M, Pfister SM, Morland B, Vassal G; Innovative Therapies for Children with Cancer (ITCC) Consortium. Moreno L, et al. Among authors: vassal g. Nat Rev Clin Oncol. 2017 Aug;14(8):497-507. doi: 10.1038/nrclinonc.2017.59. Epub 2017 May 16. Nat Rev Clin Oncol. 2017. PMID: 28508875 Free article. Review.
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.
Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD. Moreno L, et al. Among authors: vassal g. Expert Opin Drug Discov. 2017 Aug;12(8):801-811. doi: 10.1080/17460441.2017.1340269. Epub 2017 Jun 26. Expert Opin Drug Discov. 2017. PMID: 28604107 Free article. Review.
From class waivers to precision medicine in paediatric oncology.
Pearson ADJ, Pfister SM, Baruchel A, Bourquin JP, Casanova M, Chesler L, Doz F, Eggert A, Geoerger B, Jones DTW, Kearns PR, Molenaar JJ, Morland B, Schleiermacher G, Schulte JH, Vormoor J, Marshall LV, Zwaan CM, Vassal G; Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium. Pearson ADJ, et al. Among authors: vassal g. Lancet Oncol. 2017 Jul;18(7):e394-e404. doi: 10.1016/S1470-2045(17)30442-4. Lancet Oncol. 2017. PMID: 28677575 Review.
345 results